Editorial
LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC
Abstract
The benefit from adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC) is modest with an overall survival (OS) benefit of only ~5% demonstrated in the Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis (1).
